Welcome to our dedicated page for ANGIODYNAMICS SEC filings (Ticker: ANGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ANGIODYNAMICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ANGIODYNAMICS's regulatory disclosures and financial reporting.
AngioDynamics EVP and CFO Stephen A. Trowbridge reported tax-related share withholdings tied to restricted stock unit vesting. On July 16, 17 and 20, 2026, a total of 12,067 common shares were disposed of at $14.14, $13.51 and $13.71 per share, respectively, to satisfy tax withholding obligations on RSUs granted in 2025, 2024 and 2022. The filing indicates these exempt dispositions were not made under a Rule 10b5-1 trading plan.
AngioDynamics Inc. executive Laura Piccinini, SVP International, reported three exempt dispositions of common stock on July 16, 17 and 20, 2026, totaling 8,228 shares, to satisfy tax withholding obligations on pre-determined vesting of restricted stock units granted on July 16, 2025, July 17, 2024 and July 20, 2022.
AngioDynamics Inc. reports that SVP Quality and Regulatory Warren Nighan Jr. had a total of 3,777 common shares withheld in three exempt dispositions on July 16, 17 and 20, 2026, at prices from $13.51 to $14.14 per share to satisfy tax withholding obligations tied to pre-determined vesting of previously granted restricted stock units. These events were not designated as occurring under a Rule 10b5-1 trading plan.
AngioDynamics Inc. President and CEO James C. Clemmer reported five exempt dispositions of common stock from July 16–20, 2026. In total, 45,711 shares were withheld at per-share prices including $14.1400, $13.5100, and $13.7100 to satisfy tax withholding obligations on previously granted restricted stock units as they vested.
AngioDynamics Inc. executive Chad Thomas Campbell, SVP/GM Vascular Access, reported tax-related dispositions totaling 3,838 shares of common stock. On July 16, 17, and 20, 2026, shares were withheld at $14.14, $13.51, and $13.71 per share to satisfy tax withholding obligations from pre-determined vesting of restricted stock units granted in 2025, 2024, and 2022.
AngioDynamics, Inc. reports on its medical technology business designing, manufacturing and selling devices used to treat cardiovascular disease and cancer. Products are organized into Med Tech (Auryon atherectomy, AlphaVac and AngioVac thrombectomy systems, NanoKnife IRE ablation, Solero microwave ablation) and Med Device lines.
The company has reshaped its portfolio by selling dialysis, BioSentry, PICC and Midline businesses and discontinuing RadioFrequency Ablation and Syntrax, while planning a shift of additional manufacturing to third-party partners, including Costa Rica, by the first quarter of fiscal 2027. NanoKnife received expanded FDA 510(k) clearance for prostate ablation and MDR CE mark approval covering pancreas, kidney, liver and prostate tumors.
AngioDynamics lists intense competition from large device makers, pricing pressure from group purchasing organizations, dependence on key suppliers and international distributors, complex global regulation and potential product-liability and compliance exposure as principal risks. It employed 632 people as of May 31, 2026, and its CEO has announced plans to retire by late 2026.
AngioDynamics reported record fiscal 2026 results, with pro forma net sales of $320.2 million, up 9.4% from a year earlier, and fourth‑quarter net sales of $86.6 million, up 8.0%. Med Tech revenue grew 18.4% to $150.0 million, while Med Device revenue rose 2.5% to $170.2 million, lifting gross margin to 54.6%.
Despite stronger sales, the company posted a GAAP net loss of $36.7 million, or $0.88 per share, though adjusted net loss was $10.0 million and adjusted EBITDA increased to $13.2 million from $7.6 million. Cash from operations was $3.1 million for the year, and AngioDynamics ended May 31, 2026 with $53.9 million in cash and a debt‑free balance sheet.
Growth was led by the Auryon atherectomy system, Mechanical Thrombectomy portfolio and NanoKnife platform, which benefited from new clinical data, FDA IDE approvals and improved reimbursement including Category I CPT codes and a Medicare local coverage determination. For fiscal 2027, the company guides net sales to $336–$341, Med Tech growth of 12–15%, gross margin of 54–55%, and adjusted EBITDA of $13–$16.
AngioDynamics, Inc. Schedule 13G/A: Point72 reports beneficial ownership of 3,181,829 shares of common stock, representing 7.7% of the class as of March 31, 2026. The shares are held by Point72 Associates; voting and dispositive power are reported as shared. Point72 Asset Management and Point72 Capital Advisors Inc. state they own no shares directly; Steven A. Cohen is reported to control the filing entities.
AngioDynamics reported higher sales but remained unprofitable for the quarter ended February 28, 2026. Revenue rose 8.9% to $78.4 million, driven by 19.0% growth in Med Tech and 1.2% growth in Med Device.
Quarterly gross margin slipped to 52.9% as tariffs, inflation and Med Device mix offset volume and outsourcing benefits. Net loss widened to $8.1 million (loss per share $0.19) from $4.4 million, largely reflecting higher restructuring and CEO transition costs.
For the nine months, revenue increased to $233.6 million (up 10.0%) and net loss improved to $25.3 million (loss per share $0.61) from $27.9 million. The company ended the period with $37.8 million in cash, no debt and access to a $25.0 million revolving credit facility while continuing a multi‑year manufacturing footprint restructuring and ongoing payments under a patent settlement with BD.